Podcasts about transplantation

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

Allein in Deutschland warten derzeit 5000 Patientinnen und Patienten auf eine Transplantation der Hornhaut; weltweit sind es sogar rund 13 Millionen Menschen. Eine künstliche Hornhaut, wie sie Oberarzt Dr. Joel Lüthy an der Asklepios Klinik Nord Heidberg im vergangenen November erstmals in Norddeutschland eingesetzt hat, könnte vielen Betroffenen schneller helfen. Wie der Eingriff funktioniert und für wen er infrage kommt, erklärt der Augenarzt in dieser Podcast-Folge.

Tamara Schwab hat mit Ende 20 ein neues Herz erhalten. Rund vier Jahre später ist sie Autorin, Trainerin für die Themen Resilienz, Change und Erfolg und außerdem Botschafterin der Deutschen Herzstiftung. Im Gespräch erzählt sie von den sichtbaren und unsichtbare Narben, die eine solche Herzverpflanzung hinterlässt – und wie man trotzdem den Lebensmut behält. Triggerwarnung: Es geht in dieser Episode um sensible Inhalte wie Tod und Transplantation.

Spenderorgane sind rar und begehrt. Daher werden auch Tiere zu Organspendern. Noch ist die Xenotransplantation im Versuchsstadium. Doch das Forschungsfeld macht enorme Fortschritte. (00:32) Tierorgane werden immer menschlicher und die Überlebenschancen von Transplantierten immer grösser. Gentechnik macht es möglich, dass die Verpflanzung von tierischen Organen allmählich zu einer realistischen Alternative wird. Bereits schon ein halbes Jahr lebt ein Mensch, der eine Schweineniere erhalten hat. Vor kurzem wurde erstmals eine Schweinelunge in einen Menschen verpflanzt. Eine besonders komplizierte Transplantation. Jetzt versammeln sich Wissenschaftler:innen in Genf zur internationalen Xenotransplantations-Konferenz IXA (Irène Dietschi) (06:42) Meldungen: - Neue Neurblastom-Therapie aus Zürich - Erste Gentherapei gegen Chorea Huntington - Gigantische Felsenkunst in der Arabischen Wüste (Katharina Bochsler (15:37) Zwei Vulkane haben ein unterirdisches Verhältnis Anfang 2025 hat es auf Santorini tüchtig gerumpelt. Eine Reihe von Erdbeben bewegte die Inselgruppe in der südlichen Ägäis. Der Vulkan unterhalb des Kykladen-Archipels war spürbar unruhig geworden. Und nicht nur er, wie sich jetzt zeigt. Mitgewirkt hat auch der sieben Kilometer entfernte submarine Vulkan Kolumbos. Denn Forschende haben jetzt entdeckt: die beiden Vulkane teilen sich eine gemeinsame Magmakammer (Anita Vonmont) (21:16) Das Konzept der wasserreichen Exoplaneten verdampft Eine ETH-Studie widerlegt die Hypothese, wonach weit draussen im Kosmos von riesigen Ozeanen bedeckte - sogenannt hyzänische - Planeten kreisen. Dieses Konzept bewohnbarer Exoplaneten schürte in den letzten Jahren die Hoffnung, Leben im All zu finden. Forschende der ETH Zürich kommen nun zum Schluss: Diese «Wasserwelten» sind wohl nur Fiktion. In der Realität würde ein Grossteil des Wassers bald nach der Geburt der Planeten durch chemische Prozesse verschwinden. (Sandro Della Torre) LINKS Xenotransplantation IXA Konferenz: ixa2025.org Neuroblastom: nature.com/articles/s41586-025-09564-0 Gentherapie Chorea Huntington: uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii Planetary health Check: planetaryhealthcheck.org Kosmische Wasserwelten: iopscience.iop.org/article/10.3847/2041-8213/adff73

AJT October 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Christina Haugen to discuss the key articles of the October issue of the American Journal of Transplantation. Dr. Christina Haugen is an Assistant Professor of Surgery at the University of Cincinnati. [03:28] Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes—An analysis of COMPARE trial data [10:26] Donor-specific mesenchymal stem cell infusion in human and nonhuman primate kidney transplantation [19:21] Potential targeting of urokinase-type plasminogen activator receptor–formyl peptide receptor signaling to prevent recurrence in posttransplant primary podocytopathies [30:20] The relationship between cessation of brain and systemic circulation after withdrawal of life-sustaining measures [36:03] Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

Hosts Roz and Dr. Sanchez-Fueyo discuss the key articles of the September issue of the American Journal of Transplantation. [03:30] Blunted cardiac reserve as a marker of cirrhotic cardiomyopathy—Cardiac outcomes following liver transplantation and comparison to the existing guidelines [14:18] Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial [25:55] Donor-derived cell-free DNA is associated with the degree of immunosuppression in lung transplantation [36:24] A two-threshold algorithm using donor-derived cell-free DNA fraction and quantity to detect acute rejection after heart transplantation [45:00] Cell therapy with human Interleukin 10–producing ILC2s enhances islet function and inhibits allograft rejection

In this episode, we are joined by Dr. Emile Bacha to discuss the emerging field of partial heart transplantation. The conversation explores the history of the concept, its reintroduction in recent years, and how techniques such as domino procedures are being developed to expand donor availability. Dr. Bacha explains the practical challenges of regulation, organ procurement, and immunosuppression, as well as early outcomes seen in paediatric patients. With reflections on valve durability, patient growth, and the future potential of this approach, this episode offers a detailed look into a promising area of congenital cardiac surgery and beyond.

Mitochondria might be one of the most important organelles inside our cells. Best known as the cell's powerhouse, they don't just make energy; they regulate metabolism, control cell death, drive immune function, and may even be the reason multicellular life exists at all!It's no surprise they're implicated in nearly every major disease, from heart disease and cancer to neurodegeneration, especially as they decline with age. What if we could slow or even reverse that decline by giving cells fresh, healthy mitochondria? That's the promise of mitochondrial transplantation—a groundbreaking approach Mitrix Bio is pioneering. In this episode, I talk with CEO Tom Benson about the science, the potential, and the early results from people already lining up for their trial.Episode Show Notes: https://livelongerworld.com/p/tbensonFind me: https://x.com/aasthajs My longevity products: https://www.livelongerworld.com/p/2024TIMESTAMPS:00:00 - Injecting new mitochondria into your body01:39 - Mitochondria's evolutionary role in aging04:35 - What happens to old mitochondria?06:18 - Why humans live longer than other animals11:30 Why cardiovascular disease is #1 killer12:30 - Why does the brain remain sharp with age?15:30 Why does energy decline after age 30?19:04 Why doesn't the body correct mitochondrial mutations?22:42 Mitochondrial defects in children24:14 Diagnostics for mitochondrial health27:36 Mitochondrial DNA is eternal33:18 Where does mitochondria come from in mitochondrial transplantation?34:59 Growing mitochondria in a bioreactor39:07 How neurons grow their mitochondria40:52 Mitochondrial theory of cancer44:23 Mitochondria and psychobiology48:32 Chemotherapy and radiation damage mitochondria50:38 Evidence that mitochondrial transplantation works56:06 Caloric restriction, sauna, sunlight, and mitochondria1:00:01 Mitochondria and races1:02:57 Why stop at 130 years old?1:04:48 Why might this not work?1:10:03 Volunteers for Mitrix trialAASTHA, LIVE LONGER WORLD:X: https://x.com/aasthajs Newsletter: https://livelongerworld.com/Instagram: https://www.instagram.com/aasthajs/Mitrix Bio: https://mitrix.bio/Tom Benson: https://mitrix.bio/team/tom-benson/RELATED:New Spin to the Free Radical Theory of Aging: https://www.livelongerworld.com/p/rosKeto & Metabolic Therapy for Cancer | Dr. Thomas Seyfried: https://open.spotify.com/episode/7tYdjcJ3G4tqbAx9Z6Bix2?si=biOOH1e5RpeZduLJv2fPHwBoost Mitochondria with Sunlight and Infrared light: https://open.spotify.com/episode/1jGfhzX1P245LU2kLwgHTq?si=yPOC3bViRnmOUeR-P0jeWA

Sonja Koppitz www.deutschlandfunkkultur.de, Plus Eins

In this week's replay episode from 3 years ago, we delve into the world of pediatric heart transplantation and the impact that race or insurance status may have on outcomes. What are the factors that explain worse outcomes for black children waiting for a heart transplant? How is the PHTS Racial Disparity Taskforce working to reduce inequities in this field? What role does insurance status have on these outcomes? We speak with noted heart failure and transplantation expert, Dr. Neha Bansal who is Associate Professor of Pediatrics at The Icahn School of Medicine at Mount Sinai about this recent PHTS multicenter study.DOI: 10.1016/j.healun.2022.12.002

Anita G. war schwanger, als eine Influenza B, ihr Leben für immer veränderte. Ihre Grippe führte zu einer schweren Lungenentzündung, einem Lungenkollaps, einem künstlichen Tiefschlaf – und schließlich zur unabwendbaren Lungentransplantation. Ihr Sohn Lucca kam zu früh auf die Welt. Leider verstarb er wenige Tage später an Lungenversagen. In dieser Folge erzählt Anita von einem Weg, den man sich nicht ausdenken kann. Vom Überleben nach der Transplantation. Vom Abschied nehmen. Und vom Weiterleben mit Schmerz, Kraft und Hoffnung. Diese Folge braucht Mut – zum Erzählen, zum Hören, zum Dableiben. Und genau deswegen ist sie so wichtig. Triggerwarnung: Diese Episode enthält Schilderungen schwerer Krankheit, Transplantation, Verlust eines Kindes und psychischer Grenzerfahrungen.www.brigitte-schmailzl.dewww.rausausdemhaus.athttps://www.organspende-info.dehttps://www.pari.com/de/home/#Atempodcast #truestory #Lungentransplantation #Atemnot #FremdeLunge #Husten #Trauerarbeit #stillegeburt #Geburt #Schwanger #Trauma #Organspende #Transplantation #inhalation #atemphysiotherapie #atemtherapie#sternenkinder

Hosts Roz and Alberto are joined by new Editorial Fellow Dr. Sofia Bin to discuss the key articles of the August issue of the American Journal of Transplantation. Dr. Sofia Bin is an assistant professor of medical and surgical sciences at the University of Bologna.   [02:46] Gut microbiome alterations precede graft rejection in kidney transplantation patients [10:31] Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: a multicenter international study Editorial: Graft biopsy reimagined: Integrating morphology and molecular maps [22:20] Does a changing donor pool explain the recent rise in the United States kidney nonuse rate? [32:45] A scintigraphic look at the dead donor rule in donation after the circulatory determination of death with the use of normothermic regional perfusion: A single-center interventional trial Editorial: Normothermic regional perfusion in donation after circulatory determination of death—Confirming the absence of brain reperfusion [37:03] Global variation in living donor liver transplantation practices impacts donor and recipient short-term outcomes: initial insights from the International LDLT Registry

Dr. Chris Wiebe shares his expertise in use of HLA eplet mismatch load in estimating immunologic risk in transplantation. We cover considerations of de novo HLA-DSA formation, donor selection, impacts on post-transplant monitoring protocols, as well as immunosuppression.

What if we could reset our cellular batteries? In this fascinating deep dive into cutting-edge longevity science, Tom Benson from Mitrix Bio reveals how mitochondrial transplantation could revolutionize how we treat age-related diseases and potentially add decades of healthy living to our lives.The conversation begins by exploring the extraordinary nature of mitochondria – those tiny power plants within our cells that generate 95% of our body's energy through molecular rotors functioning like miniature jet turbines. With approximately a quadrillion mitochondria comprising 10% of our body weight, these ancient organelles trace back to a symbiotic merger with our cellular ancestors over a billion years ago.Unlike the nuclear DNA we inherit from both parents, our mitochondrial DNA comes almost exclusively from our mothers, creating fascinating maternal lineage patterns where thousands of family members share identical mitochondrial DNA. As we age, this mitochondrial DNA gradually accumulates damage, with factors like stress, smoking, and medical treatments accelerating deterioration. By our 90s, this decline reaches a critical threshold that appears to drive much of the aging process.The most exciting revelation comes in learning that mitochondria naturally move between cells in our bodies – and scientists are now leveraging this phenomenon through transplantation techniques. By harvesting mitochondria from stem cells grown in bioreactors and reinjecting them, researchers are seeing remarkable improvements in cognition, strength, and immune function in aged mice, essentially restoring youthful cellular energy levels. Human trials are already underway, though still at small scale.For anyone fascinated by the frontiers of longevity science and the quest to not just add years to life, but life to those years, this conversation offers a glimpse into one of the most promising approaches emerging today. https://mitrix.bio/Lies I Taught In Medical School : Free sample chapter- https://www.robertlufkinmd.com/lies/Complete Metabolic Heart Scan (20% off 'LUFKIN20') https://www.innerscopic.com/Fasting Mimicking Diet (20% off) https://prolonlife.com/Lufkin At home blood testing (20% off) https://siphoxhealth.com/lufkinMimio Health (15% off 'LUFKIN') https://mimiohealth.sjv.io/c/5810114/2745519/30611 Web: https://robertlufkinmd.com/X: https://x.com/robertlufkinmdYoutube: https://www.youtube.com/robertLufkinmdInstagram: https://www.instagram.com/robertlufkinmd/LinkedIn: https://www.linkedin.com/in/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinThreads: https://www.threads.net/@robertlufkinmdFacebook: ...

Your Health First: Advancements in Robotic Surgery & Live Liver Donation at Houston MethodistJoin Dr. Joe Galati on this episode of "Your Health First" as he speaks with leading surgeons from Houston Methodist Hospital, Dr. Simon and Dr. Yee Lee Cheah. Broadcasting live from 740 KTRH in Houston and worldwide on the iHeartRadio app every Sunday at 7:00 PM Central, this insightful discussion delves into the groundbreaking work being done in robotic surgery and the current status of the live donor liver transplant program at Houston Methodist.Dr. Simon and Dr. Cheah share their expertise on the numerous benefits of robotic surgery, highlighting the significant advantages for patients and the remarkable advancements in technology over the past 5-10 years. They also provide a comprehensive overview of the meticulous patient selection process for live liver donors and detail the structured program at Houston Methodist Hospital.Don't miss this opportunity to learn about the cutting-edge surgical techniques and life-saving transplant procedures making a difference in patient care.For more information:Dr. Simon & Dr. Cheah: www.houstonmethodist.orgDr. Joe Galati: www.drjoegalati.comGuest Biographies:Dr. Simon:Dr. Simon is a highly accomplished surgeon with a specialization in abdominal transplantation and hepatobiliary surgery. She earned her medical degree with honors from University College Cork Faculty of Medicine in Ireland in 2002 and completed her general surgery residency at Brown University Program, Rhode Island Hospital. Dr. Simon further honed her expertise with a research fellowship in Diagnostic Imaging at Brown University and an ASTS-certified fellowship in Abdominal Transplantation and Hepatobiliary Surgery at Lahey Hospital & Medical Center. Her clinical interests are extensive, encompassing both benign and malignant tumors of the liver, bile duct, and pancreas, including hepatocellular carcinoma and Klatskin tumors. She is also deeply involved in kidney transplantation, living and deceased donor liver transplantation, pancreatic carcinoma, robotic surgery, and surgery for portal hypertension. Dr. Simon is board-certified in general surgery by the American Board of Surgery and is a Fellow of the American College of Surgeons (FACS).Dr. Yee Lee Cheah:Dr. Yee Lee Cheah is a distinguished surgeon who joined the J.C. Walter Jr. Transplant Center at Houston Methodist Hospital in 2022. She graduated with honors from the Royal College of Surgeons in Ireland in 2000 and completed her General Surgery Residency at the Brown University Program. Dr. Cheah further specialized with an ASTS-accredited fellowship in Transplantation & Hepatobiliary Surgery at the Lahey Clinic. Prior to Houston Methodist, she played a pivotal role at the Asian American Liver Centre at Gleneagles Hospital, the largest adult living donor liver transplantation (LDLT) center in Southeast Asia, before returning to LHMC to develop their LDLT and robotic surgery programs. Her expertise lies in living donor liver transplantation, robotic transplantation, HPB surgery for benign and malignant disorders, and nutrition therapy for surgical patients. Dr. Cheah's main research interests are centered on living donor safety and robotic surgery. She has held faculty positions at Brown University and Tufts University and served as an Adjunct Assistant Professor at the National University of Singapore. Hosted on Acast. See acast.com/privacy for more information.

Alles Gute (nachträglich) zum Geburtstag, Heiko "Snäcki" Postel. Er will sich im Sommer Haare einpflanzen lassen. Die Freeses schenken ihm ein paar davon, beziehungsweise das Geld dafür. Jederzeit und so oft ihr wollt: Die NDR 2 Kult-Comedy direkt aus dem Mehrgenerationen-Haushalt der Familie Freese. Die Lasziv-zupackende Oma Rosi, Helikopter-Mama Bianca, Sohn Svenni und Untermieter und Labertasche Heiko: Die besten Folgen bekommt ihr jeden Morgen in der ARD Audiothek.

Hosts Roz and Alberto discuss the key articles of the July issue of the American Journal of Transplantation. [03:48] Liver transplantation for hepatitis D virus/hepatitis B virus coinfection in Italy: an intention-to-treat analysis of long-term outcomes [13:42] 10 degree C static storage of porcine donation after circulatory death livers improves biliary viability and mitigates ischemia-reperfusion injury [22:20] Fewer medullary pyramids in the living kidney donor are associated with graft failure in the recipient [33:35] Microvascular inflammation in kidney allografts: New directions for patient management MOMOT (Mouse Models in Transplant) articles: Can mouse kidney transplant models inform mechanisms of injury and acceptance in clinical kidney transplantation? Best practices in islet transplantation in mice

Guest: Andrew Goldstone, M.D., Ph.D. On this episode of Advances in Care, host Erin Welsh talks to Dr. Andrew Goldstone, pediatric cardiac surgeon at NewYork-Presbyterian and Columbia, about the groundbreaking heart transplant that saved the lives of three separate children. It was the first time doctors at NewYork-Presbyterian Morgan Stanley Children's Hospital performed a split-root domino partial heart transplant. In this procedure, one child was transplanted with a new heart and their original heart was used to donate living pulmonary and aortic valves to two separate recipients in need. Dr. Goldstone, his colleague Dr. David Kalfa, and the rest of the team at NewYork-Presbyterian and Columbia had previous experience with a handful of domino partial heart transplants where one patient is transplanted with a new heart and another receives a valve from the explanted heart. Those experiences helped prepare for the split-root domino, which took nearly 24 hours of extremely coordinated care. In addition to their efforts to increase the number of domino heart transplants being done, physician-researchers at the institution are leading new studies that are also helping improve living valve procurement and storage, allowing more children to receive heart valves that will grow with them and require less surgeries. © 2025 …

This week we speak with congenital heart surgeon T. Konrad Rajab of Arkansas Children's Hospital about a recent report he co-authored on piglet experiments on partial heart transplantation. How did transplanted heart valves grow in comparison to standard homografts and how did the valvular function differ with time? Is there a minimum dose of immunosuppresion that can protect these valves and can this dose be lower than full heart transplantation immunosuppresion therapy? Is partial heart transplantation considered a potential life-long approach to valve replacement or mostly something used to allow for growth of valves during childhood? What do we know about the world's limited experience in humans of this approach? Dr. Rajab shares the answers this week in an exciting 'sci-fi' episode. The future is now.https://doi.org/10.1016/j.jacbts.2024.10.015

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

Un bébé né après une transplantation utérine Les brèves du jour Quand la mode mettait notre santé en péril One Health: lutte contre les moustiques résistants et enjeux climatiques "Papa Tango Charlie" (1976) de Mort Shuman et Philippe Adler pour parler du triangle des Bermudes

Commentary by Satish Raj.

An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Societyfor Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University HealthStephenson Cancer Center and serves as an ambassador for ASCO.The group highlighted several late-breaking abstracts,plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:Phase 1b/2 CARTITUDE-1 trial (NCT03548207,NCT05201781)1Long-term follow-up showed that approximately one-third(33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti). An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-notevaluable [NE]). Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use2Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.Phase 1b/2 NEXICART-2 trial (NCT06097832)3Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.Among 12 patients who received the agent at 450x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively. With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.References1.     Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.75072.     Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-celllymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.70233.     Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508.doi:10.1200/JCO.2025.43.16_suppl.7508

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University Health Stephenson Cancer Center and serves as an ambassador for ASCO. The group highlighted several late-breaking abstracts, plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following: ·       Phase 1b/2 CARTITUDE-1 trial (NCT03548207, NCT05201781) o   Long-term follow-up showed that approximately one-third (33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti).  o   An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas. o   With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-not evaluable [NE]). ·       Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use o   Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma. o   Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. o   Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings. ·       Phase 1b/2 NEXICART-2 trial (NCT06097832) o   Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options. o   Among 12 patients who received the agent at 450 x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively.  o   With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred. References 1. Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.7507 2. Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.7023 3. Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508. doi:10.1200/JCO.2025.43.16_suppl.7508

Host Roz is joined by new co-host Alberto Sanchez-Fueyo, MD, PhD to discuss the key articles of the June issue of the American Journal of Transplantation. Dr. Sanchez-Fueyo is a Professor of Hepatology, and the Academic Director of the Institute of Liver Studies, King's College, London. [02:51] Recipient toll-like receptor 4 determines the outcome of ischemia-reperfusion injury in steatotic liver transplantation in mice [10:47] Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study [21:35] Balancing equity and human leukocyte antigen matching in deceased-donor kidney allocation with eplet mismatch Editorial: Equitable allocation through human leukocyte antigen eplet matching: A promising strategy with several challenges [32:51] Impact of the lung allocation system score modification by blood type on US lung transplant candidates Editorial: From flawed to fairer: Reducing blood type bias in lung transplant allocation Recommended article: The economic value of a transplant nephrologist: The case for improving compensation models

In this specialty podcast, Dr. Alissar El Chediak is joined by Dr. Jon Odorico and Dr. Ron Parsons to discuss the current state of pancreas transplantation, identify barriers and strategies for referral and candidate selection, and discuss solutions to address the decline in procedures. Alissar El Chediak, MD is a transplant nephrologist at UT Southwestern Medical Center. Jon Odorico, MD is a transplant surgeon at the University of Wisconsin. Ron Parsons, MD is a transplant surgeon at the University of Pennsylvania.   References: Generating strategies for a national comeback in pancreas transplantation: A Delphi survey and US conference report

Should animals ever be used as spare parts for humans? PETA Sr. VP Kathy Guillermo was interviewed by CNN about xenotransplantation.  Listen to what she had to say about the experience and the hope that her views are represented fairly.  See PETA represent the ethical perspective on xenotransplantation in the CNN documentary "Animal Pharm," which premieres Sunday, May 17. Find out more about xenotransplantation, go to PETA.org The PETA Podcast PETA, the world's largest animal rights organization, is 9 million strong and growing. Hosted by Emil Guillermo.  Contact us at PETA.org Music provided by CarbonWorks. Go to Apple podcasts and subscribe. Contact and follow host Emil Guillermo and get the podcast on YouTube. www.YouTube.com/@emilamok1 Please subscribe, rate, and review wherever you get your podcasts. Thanks for listening to THE PETA PODCAST! Originally released May 14, 2025,  ©PETA, Emil Guillermo 2023-25  

In this extraordinary episode, Prue shares her remarkable 11-year journey to motherhood, culminating in becoming the third woman in Australia to give birth following a uterus transplant. Her story is one of incredible perseverance, medical innovation, and the profound desire to become a mother against seemingly impossible odds. If you've been considering joining over 6000 families who have prepared for birth with confidence through The Birth Class now's your chance. You can enjoy 20% off in our Mother’s Day Sale with the code: MUM25Inside The Birth Class you’ll enjoy: 10 comprehensive audio lessons 5 guided meditations for pregnancy and birth 70-page detailed workbook Birth partner cheat sheet Birth positions poster Hospital bag checklist Birth preferences template Lifetime access Save 20% Now [ Code: MUM25 ] Sale ends 15th of May at midnight and applies to all our courses!See omnystudio.com/listener for privacy information.

In a special co-branded episode between Oncology On theGo hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Nora M. Gibson, MD, MSCE, and Taha Al-Juhaishi, MD, spoke about real-world applications of betibeglogene autotemcel (beti-cel; Zynteglo) as a treatment for patients with beta (β)-thalassemia.They spoke in the context of a study that Gibson presented at the 2025 Tandem Meetings, which evaluated patients who received commercial beti-cel in a single-center cohort following the agent's FDA approval in August 2022. ¹ ²Nora is a fourth-year fellow in bone marrow transplant andcellular therapy at the Children's Hospital of Philadelphia (CHOP), with a background in clinical research and epidemiology. Al-Juhaishi is the Associate Director of the Hematopoietic Stem Cell Transplantation and Cell TherapyProgram at Oklahoma University Health Stephenson Cancer Center and an assistant professor of Medicine at the University of Oklahoma College of Medicine.Findings from Gibson's study revealed that among 10 patients who underwent stem cell collection at CHOP from 2022 to 2024, beti-cel yielded consistent red blood cell transfusion independence, with investigators notingprolonged platelet engraftment time and high platelet transfusion requirements. Beyond these findings, the conversation focused on how beti-cel compares withother currently available gene therapies for patients with hemoglobin disorders as well as non-curative therapies like allogeneic stem cell transplantation. Gibson and Al-Juhaishi also discussed strategies for mitigating occlusive disease and other potential toxicities associated with beti-cel.“It's a really exciting time to be working in this fieldwhere we finally have really good options for these patients. From our experience and from clinical trials, beti-cel and likely exagamglogene autotemcel [Casgevy]...are very effective, curative therapies for thalassemia in the real-world setting, and we've seen very similar results in sickle celldisease,” said Gibson. “These therapies have been really life-changing for our patients, and they've had a huge reduction in their symptoms and a huge reduction in their burden of health care that's required.”References1.     Gibson NM, Friedman DF, Elgarten CW, et al. Post-approval, real-world experience with betibeglogene autotemcel for transfusion-dependent betathalassemia. Transplantation and Cellular Therapy. 2025;31(2):S254. doi:10.1016/j.jtct.2025.01.386.2.     FDA approves first cell-based gene therapy totreat adult and pediatric patients with beta-thalassemia who require regular blood transfusions. News Release. FDA. August 17, 2022. Accessed April 21, 2025.https://tinyurl.com/3vrkk8kz

Host Roz is joined by Timucin Taner, MD, PhD and Dami Ko, PhD to discuss the key articles of the May issue of the American Journal of Transplantation. Dr. Timucin Taner is a professor of surgery at Mayo Clinic, Rochester, MN. Dr. Dami Ko is an assistant professor at the School of Nursing at Northeastern University. [02:51] Development and validation of the Neuro-Score: a specific scale to detect and monitor cognitive impairment in kidney or liver transplant recipients Editorial: Cognitive impairment after liver and kidney transplant: An easy way to check [14:16] Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression [20:46] Donor-specific immune senescence as a candidate biomarker of operational tolerance following liver transplantation in adults: Results of a prospective, multicenter cohort study Editorial: Acquired immune tolerance 2.0 [29:10] Major histocompatibility complex and peptide specificity underpin CD8+ T cell direct alloresponse Editorial: Direct and indirect allorecognition—not so different after all?

Dr. Justin Abbatemarco provides an update on autologous hematopoietic stem cell transplantation in multiple sclerosis. Show reference: https://www.nature.com/articles/s41582-024-01050-x

Host: Darryl S. Chutka, M.D. Guest: John Haney, M.D., M.P.H. Lung transplantation remains a very viable option for patients with end-stage pulmonary disease who no longer respond to medical management. Over 5,000 lung transplants are performed annually around the world. However, its estimated that over 10 times this number are candidates and awaiting a transplant. A shortage of organs remains the major limiting factor. What are the common indications and who's a candidate for a lung transplant? How are patients prioritized and chosen? What advances have been made in the field and what challenges remain? Finally, what role does the primary care clinician play in lung transplantation? I'll be discussing these questions and more with my guest, Jack Haney, M.D., M.P.H., chair of cardiothoracic surgery at the Jacksonville campus of the Mayo Clinic. The topic for this podcast is “Lung Transplantation”. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on X @MayoTransplant. To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Host Roz is joined by Rene Bermea, MD and Gonzalo Sapisochin, MD, PhD to discuss the key articles of the April issue of the American Journal of Transplantation. Dr. Rene Bermea is an instructor at Harvard Medical School, and a transplant pulmonologist and intensivist. Dr. Gonzalo Sapisochin is an associate professor of surgery, abdominal transplant and surgical oncology at the University of Toronto, Canada. [04:31] Generalizability of kidney transplant data in electronic health records — The Epic Cosmos database vs the Scientific Registry of Transplant Recipients Editorial: Finding actionable information in the universe of data [14:17] High-dimensional profiling of immune responses to kidney transplant reveals heterogeneous T helper 1 and B cell effectors associated with rejection Editorial: Multimodal profiling of transplant rejection: Discerning the forest from the trees [23:02] The ability of an electronic nose to distinguish between complications in lung transplant recipients [34:58] The Rochester Protocol for living donor liver transplantation of unresectable colorectal liver metastasis: A 5-year report on selection, approval, and outcomes

Host: Darryl S. Chutka, M.D. Guest: Rohan M. Goswami, M.D. The benefits of artificial intelligence or AI are just beginning to be recognized. AI has the potential to improve productivity and efficiency in the workplace, reduce errors and help sort out complex issues. The field of healthcare is finding roles for AI by improving the management of patient data, enhancing clinical decision making and assisting in medical imaging analysis. The integration of AI in transplantation medicine is evolving and has the potential to revolutionize the field. Can AI assist in organ matching and allocation? Can it predict graft survival and organ rejection?  What ethical concerns does AI bring to the specialty?  I'll be discussing these issues in this podcast as we tackle the topic of “AI in Transplantation Medicine”. My guest for this podcast is Rohan M. Goswami, M.D., a cardiologist and specialist in Transplant Medicine from the Mayo Clinic. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on X @MayoTransplant. To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Our next AAOS 2025 Annual Meeting poster is titled Mid-term Follow-up of Patellofemoral Osteochondral Allograft Transplantation. This study was performed by Dr. Bill Bugbee and his team at the Scripps Clinic. Dr. Bugbee was a guest on our show back in November 2023.  That is episode 59 and 60, if you want to go check it out.  In that episode, we discussed osteochondral allograft transplantation for various cartilage defects of the knee, including medial and lateral tibiofemoral, which are the more common locations for OCA transplantation.  This study focuses specifically on outcomes of OCA transplantation for patellofemoral cartilage defects.This study identified 127 patients undergoing OCA transplantation in the patellofemoral compartment – 51 to the patella, 47 to the trochlea and 29 bipolar patella and trochlea.  The most common indication was a degenerative cartilage lesion at 47%, followed by a traumatic cartilage injury at 25% and osteochondritis dissecans at 15%.  All patients had a minimum follow-up of 2 years.  OCA failure was defined as any reoperation that involved removal of the allograft.  Patient reported outcomes were also assessed pre-op and post-op, including the IKDC score and KOOS score.So, what did this study find?  First, reoperations occurred in 39% of the knees.  Rate of reoperation was not statistically significant between patella, trochlea and bipolar grafts.  Second, OCA failures occurred in 16% of the knees at a median 4.4 years following the index surgery, and the most common revision procedure was arthroplasty.  Although it did not reach statistical significance, trochlear grafts had a lower failure rate of 9% compared to patellar grafts at 20% and bipolar grafts at 21%.Overall, graft survivorship at 5 and 10 years was 91% and 82%, respectively.  Patients with patellar, trochlear and bipolar grafts all had significant improvement in IKDC scores and KOOS scores from preop to the latest follow-up and no statistically significant differences were observed between the groups.  Overall, 77% of patients reported being satisfied with the results of the OCA transplantation with no statistically significant differences in satisfaction between the groups.Also check out:Episode 91: Dr. Tom DeBerardino 0n Advances in Patellofemoral Cartilage Restoration

Host: Darryl S. Chutka, M.D. Guests: Nitin N. Katariya, M.D., and Lavanya Kodali, M.B.B.S., M.D. At this time, about 11% of the population in the U.S. has diabetes.  This represents nearly 40 million people. And this number is increasing, not only in the U.S. but around the world. Although we have more medical options now than ever before for managing diabetes, the treatment is less than optimal. Another option is a pancreas transplant. What's the status of pancreatic transplantation? Who's a candidate for the procedure? How effective is it and what does the future hold for the procedure?  The topic for this podcast is “Pancreas Transplantation” and I'll be discussing these questions with Nitin N. Katariya, M.D., a transplant surgeon and Lavanya Kodali, M.B.B.S., M.D., a nephrologist and specialist in renal transplant, both from the Arizona campus of the Mayo Clinic. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on Twitter @MayoTransplant To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Host: Darryl S. Chutka, M.D. Guest: C. Burcin Taner, M.D. Recently, the criteria for organ donors have expanded in order to address the increasing difference between the number of available organs and the demand for transplants. Advancements in medical technology, a better understanding of transplant immunology, and the improvement of transplant surgery techniques have allowed for the inclusion of a greater pool of donors with various health conditions, which excluded them as donors in the past. Understanding the delicate balance between expanding the criteria for transplantation and maintaining a high quality of life for the recipients has been important in advancing the field of organ transplantation. The topic for this podcast is “Expanded Donor Criteria for Organ Transplantation” and my guest is C. Burcin Taner, M.D., Professor of Surgery and Chair of the Department of Transplantation at the Florida campus of the Mayo Clinic. Learn more about our Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on Twitter @MayoTransplant To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

This week we review a recent PHTS study on long-term outcomes following heart transplantation. Why do patients develop coronary vasculopathy and how commonly is it seen at long term follow-up? What factors are associated with better or worse long term outcomes? How do 'adverse childhood experiences' result in worse outcomes for patients? Why do young transplant patients have better long-term outcomes and can this be leveraged to improve older patient outcomes? We speak with the first author of this week's work, Assistant Professor of Pediatrics at Ohio State and also from Nationwide Children's Hospital, Dr. Emily Hayes. DOI: 10.1111/petr.70042

This week on Health Matters, Courtney Allison is joined by infectious disease expert from NewYork-Presbyterian and Columbia, Dr. Marcus Pereira, to learn what we need to know about bird flu.Dr. Pereira explains that while the cases of bird flu in humans have been mostly mild, there is still a risk that the virus could mutate and spread more easily from human-to-human. He talks about ways to protect ourselves from bird flu, and explains whether it's safe to eat eggs, meat and other dairy products.___Dr. Marcus Pereira is an Associate Professor of Medicine at CUMC and the Director of Clinical Services in the Division of Infectious Diseases. In addition, he is the Medical Director of the Transplant Infectious Diseases Program, where he oversees the development of infection prophylaxis and treatment protocols for immunocompromised patients. His areas of interest include the management of multi-drug resistant bacterial and fungal infections, as well as drug resistant CMV infections and more recently the impact of COVID-19 in transplant recipients. He has also collaborated in important multi-center studies as well as the 2025 International CMV Guidelines, sponsored by the Transplantation Society. Dr. Pereira is an active member in national societies such as the American Society of Transplantation and Infectious Disease Society of America, and is an Associate Editor for the American Journal of Transplantation.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine. To learn more visit: https://healthmatters.nyp.org

The process of liver transplantation involves many complexities, and each patient's path to transplant is unique. To offer insider perspectives on this process, Dr. Zachary Berman sits down with transplant and hepatobiliary surgeon Dr. John Seal, as well as transplant hepatologists Dr. Heather Patton and Dr. Steve Young. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125740 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The panel begins by discussing the multidisciplinary pre-transplant evaluation process, which assesses factors such as liver function, comorbidities, surgical risk, and the availability of psychosocial support. Once a patient is listed for transplant, they enter a system that prioritizes those with the highest Model for End-Stage Liver Disease (MELD) score. During the waiting period, several comorbidities should be carefully monitored. Dr. Seal explores the impact of portal vein hypertension and portal vein thrombosis, explaining how these conditions may necessitate intraoperative thrombectomy or bypass. Dr. Patton and Dr. Young focus on considerations for using anticoagulation in patients with a high baseline bleeding risk and selecting the appropriate anticoagulant for patients listed for transplant. For patients with hepatocellular carcinoma (HCC), eligibility for MELD exception points may depend on factors such as time spent on the waiting list, adherence to the Milan criteria, and the presence of extrahepatic complications of liver disease. The panel also discusses bridging therapies to transplant, including Y90 and TACE. In the peri-transplant phase, they highlight innovations such as living donor transplants, liver perfusion pumps, and the use of hepatitis C- and HIV-positive organs. Finally, the discussion turns to post-transplant considerations, including surgical complications, organ rejection, immunosuppression, predictors of HCC recurrence, and long-term surveillance. --- TIMESTAMPS 00:00 - Introduction 01:16 - Current Landscape of Liver Transplantation 03:22 - Transplant Evaluation Process 09:48 - Timeline from Listing to Transplantion 11:16 - Treating Portal Vein Thrombosis and Hypertension 18:44 - MELD Exception Points 22:05 - Bridging Therapies 25:34 - Peri-Transplant Considerations 30:53 - Post-Transplant Period 37:39 - Repeat Transplantation --- RESOURCES Model for end-stage liver disease (MELD) and allocation of donor livers (Wiesner et al, 2003): https://www.gastrojournal.org/article/S0016-5085%2803%2950022-1/fulltext Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis- Milan Criteria (Mazzaferro et al, 1996): https://pubmed.ncbi.nlm.nih.gov/8594428/ Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database (Mehta et al, 2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC6445634/ CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf